The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study

Trial Profile

The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms EXPRESS-GC
  • Most Recent Events

    • 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Mar 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top